Clinical and Developmental Immunology
Volume 2013 (2013), Article ID 924363, 5 pages
http://dx.doi.org/10.1155/2013/924363
Review Article
1Department of Rheumatology and Clinical Immunology, The First Hospital of Xiamen University, Xiamen 361003, China
2Basic Medical Department of Medical College, Xiamen University, Xiamen 361003, China
3Department of Immunology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
2Basic Medical Department of Medical College, Xiamen University, Xiamen 361003, China
3Department of Immunology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
Received 3 May 2013; Accepted 13 August 2013
Academic Editor: Jianying Zhang
Copyright © 2013 Lihua Duan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Abstract
Interleukin-33 (IL-33), a novel member of IL-1 family, has been recently implicated in several inflammatory and autoimmune diseases. IL-33 can be produced by various types of tissues and cells and induce gene expression of Th2-associated cytokines via binding to the orphan receptor ST2. By promoting Th2 type immune response, IL-33 plays important roles in the allergy, whereas its function in autoimmune diseases attracts more attention. Recent studies reported the correlation of IL-33 with rheumatic diseases, and most of them found that the IL-33 expression levels were consistent with disease activity and development. Furthermore, evidence has indicated that IL-33-related treatment may ameliorate the pathogenic conditions and attenuate disease progression of those rheumatic diseases. Therefore, elucidation of the roles of IL-33 in rheumatic diseases would be beneficial to understand the pathogenesis and therapy of these diseases. In this paper, we will summarize the roles of IL-33 in the rheumatic diseases.
No comments:
Post a Comment